Table 4. Generalized estimating equation (GEE) model for the subtypes of fluoroquinolones on Achilles tendinopathy Korean children with pneumonia exposed to fluoroquinolones (6,229 episodes) from 2002 to 2017.
| No. of population | AT (%) | Univariate | Multivariate | |||||||
| OR | 95% CI | P | aOR | 95% CI | P | |||||
| FQ subtypes | Ciprofloxacin | 2,249 | 8 (0.36) | Ref. | Ref. | |||||
| Levofloxacin | 2,545 | 4 (0.16) | 0.44 | (0.13–1.46) | 0.1809 | 0.49 | (0.14–1.66) | 0.2501 | ||
| Moxifloxacin | 725 | 0 | – | – | – | – | – | – | ||
| Gemifloxacin | 168 | 0 | – | – | – | – | – | – | ||
| Garenoxacin | 0 | 0 | – | – | – | – | – | – | ||
| Sparfloxacin | 8 | 0 | – | – | – | – | – | – | ||
| Lomefloxacin | 23 | 0 | – | – | – | – | – | – | ||
| Ofloxacin | 351 | 0 | – | – | – | – | – | – | ||
| Tosufloxacin | 89 | 0 | – | – | – | – | – | – | ||
| Others | 71 | 0 | – | – | – | – | – | – | ||
| Duration of FQs (per 1 day increment) | 0.92 | (0.77–1.1) | 0.3679 | 0.93 | (0.78–1.1) | 0.3905 | ||||
| Age | <8 | 933 | 0 | – | – | – | – | – | – | |
| 8–12 | 501 | 3 (0.6) | 3.2 | (0.86–11.87) | 0.0816 | 2.98 | (0.79–11.18) | 0.1054 | ||
| ≥12 | 4,795 | 9 (0.19) | Ref. | |||||||
aORs, adjusted for age, severity, sex, cardiovascular diseases, congenital respiratory diseases, neuromuscular diseases, genetic metabolic diseases, neoplasms, autoimmune disease, and transplantation. AT, occurrence of Achilles tendinopathy.